Hansa Biopharma AB Share Price Mexican S.E.
Equities
HNSA N
SE0002148817
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
160.8 MXN | -.--% | -.--% | -.--% |
05-21 | Hansa Biopharma to Present Data At 2024 American Transplant Congress Annual Meeting | CI |
04-18 | Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024 |
Sales 2024 * | 239M 22.4M 382M 1.76B | Sales 2025 * | 343M 32.09M 547M 2.53B | Capitalization | 2.7B 252M 4.3B 19.88B |
---|---|---|---|---|---|
Net income 2024 * | -735M -68.83M -1.17B -5.42B | Net income 2025 * | -712M -66.68M -1.14B -5.25B | EV / Sales 2024 * | 13.2 x |
Net Debt 2024 * | 474M 44.39M 756M 3.5B | Net Debt 2025 * | 733M 68.68M 1.17B 5.41B | EV / Sales 2025 * | 10 x |
P/E ratio 2024 * |
-3.7
x | P/E ratio 2025 * |
-4.39
x | Employees | 166 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.64% |
Latest transcript on Hansa Biopharma AB
Managers | Title | Age | Since |
---|---|---|---|
Søren Tulstrup
CEO | Chief Executive Officer | 59 | 19/03/18 |
Hitto Kaufmann
CTO | Chief Tech/Sci/R&D Officer | 53 | 11-30 |
Achim Kaufhold
CTO | Chief Tech/Sci/R&D Officer | 66 | 28/05/20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 73 | 28/05/18 | |
Peter Nicklin
CHM | Chairman | 61 | 29/06/22 |
Mats Blom
BRD | Director/Board Member | 59 | 21/05/19 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+48.67% | 56.69B | |
-2.76% | 41B | |
+36.42% | 38.11B | |
-11.22% | 26.89B | |
+9.25% | 25.59B | |
-23.10% | 18.59B | |
+1.88% | 12.39B | |
+26.43% | 11.99B | |
+21.74% | 11.88B |
- Stock Market
- Equities
- HNSA Stock
- HNSA N Stock